Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Ark Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$14,730,261

810 payments

Through program year 2025, Ark Clinical Research LLC is reported as receiving $14,730,261 in research payments, across 810 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $6,096,938 235
2024 Research $3,639,367 157
2023 Research $2,021,573 276
2022 Research $1,174,970 72
2021 Research $1,638,913 59
2020 Research $9,000 2
2019 Research $149,500 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $4,573,680 47 payments
  2. ViiV Healthcare Company $2,655,737 17 payments
  3. Moderna TX, Inc. $2,512,378 268 payments
  4. Janssen Research & Development, LLC $2,424,987 92 payments
  5. GlaxoSmithKline, LLC. $1,342,412 73 payments
  6. Pfizer Inc. $728,206 55 payments
  7. Regeneron Pharmaceuticals, Inc. $252,624 146 payments
  8. Cipla USA Inc. $149,500 9 payments
  9. Dermavant Sciences, Inc. $48,684 71 payments
  10. Boehringer Ingelheim Canada Ltd.Ltee $21,454 28 payments
Studies the money was for Research payments · program years 2019–2025
  1. Phase 1, Open-Label, Randomised Crossover Study Assessing the Tolerabi $2,655,737 17 payments
  2. A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2 $1,768,762 25 payments
  3. A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (Achieve-2) $1,375,152 4 payments
  4. A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age $1,175,215 171 payments
  5. A Phase I/II Observer-Blind, Randomized, Multi-Center Trial to Evaluat $1,122,352 39 payments
  6. A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial $654,507 4 payments
  7. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $620,064 34 payments
  8. A Randomized double blind Placebo Controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S Administered As Single Dose And Two Dose Schedules in Healthy Adults $400,119 40 payments
  9. A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $365,926 16 payments
  10. A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Mrna-1403, A Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults 18 Years of Age $358,883 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record